Noticias y Actividades de AIM ImmunoTech
Ejecutivos
Ver el organigrama con sus 9 ejecutivos principales
Biografías más buscadas en AIM ImmunoTech
- Thomas Equels, Executive Vice Chairman, Chief Executive Officer an...
- Stewart Appelrouth, Director
- William Mitchell, Chairman of the Board
Recientes movimientos de ejecutivos en AIM ImmunoTech
- David Chemerow, se ha incorporado a la empresa como Independent Director (noticia publicada el 27 de febrero de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en AIM ImmunoTech.
Biotecnología
AIM ImmunoTech tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Glycomine acaba de anunciar una recaudación de fondos de 115 millones de dólares. (publicado el 22 de abril de 2025).
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de AIM ImmunoTech
- Press Releases | AIM Immunotech
- AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
- AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
- AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
- AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
- AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
- View more press releases Close
Redes sociales sobre AIM ImmunoTech
- AIM ImmunoTech en Wikipedia, Google News y Yahoo Finance
- AIM ImmunoTech en LinkedIn, Twitter y YouTube
